A new approach that uses an algorithm to analyse retinal images could help practitioners select the best treatment for patients...
Read moreDetailsEuropean drug regulators have followed in the footsteps of their Australian and US counterparts, following the approval of Novartis’ new...
Read moreDetailsThe UK’s national health provider has started treating patients with Leber's Congenital Amaurosis (LCA) with a new sight-restoring gene therapy....
Read moreDetailsA former backpacker accommodation is being transformed into a new eye health clinic in Broome, featuring three resident ophthalmologists available...
Read moreDetailsA surgeon at the University of Pittsburgh Medical Center (UPMC) has implanted the first patient in the US with a...
Read moreDetailsA Melbourne researcher has received a major funding boost to progress development of a tissue-engineered corneal endothelium for transplant, which...
Read moreDetailsIn a discovery that could have significant implications for how age-related ocular diseases are diagnosed and treated, researchers have pinpointed...
Read moreDetailsA new study has demonstrated that a particular biomarker can be used to select which age-related macular degeneration (AMD) patients...
Read moreDetailsAustralia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the...
Read moreDetailsMelbourne biopharmaceutical company Opthea has completed the patient recruitment phase for the latest trial of its novel therapy for diabetic...
Read moreDetailsInsight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited